Announcements Trials
Browse Landscape

Phase

Phase 2 150Phase 1 50Phase 3 44Phase 1/2 37Phase 4 8Phase NA 5Phase 2/3 4Phase EARLY_PHASE1 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Respiratory Tract Diseases 1Neoplasms 1MET Positive 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Brain Neoplasms 1

Interventions

Pemetrexed 13Carboplatin 13Docetaxel 11Cisplatin 11pembrolizumab 9Paclitaxel 8Gemcitabine 7Erlotinib Hydrochloride 4Bevacizumab 4anlotinib 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Gefitinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2cemiplimab 2auricularum 2atezolizumab 2apatinib 2Vemurafenib 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2Ramucirumab 2Calcium Dobesilate 2trametinib 1toripalimab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Non-Small-Cell Lung × Erlotinib Hydrochloride × Clear all
NCT03653546 2025-09-10

BM

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 2/3 Completed
492 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT01407822 2018-09-11

EMERGING

Guangdong Association of Clinical Trials

Phase 2/3 Unknown
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03074864 2017-03-09

TREND

Guangdong Provincial People's Hospital

Phase 2/3 Unknown
90 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01383148 2017-01-05

TIME

Transgene

Phase 2/3 Terminated
222 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡